.jpg)
Precision oncology has found in artificial intelligence a fundamental ally to interpret the biological complexity of cancer. Predicting how a tumor will respond to a specific drug based on transcriptomic profiles is a challenge that goes beyond numerical accuracy; models need not only to be correct, but to explain why they are correct. However, many current explainability techniques remain at univariate assessments, assigning scores to individual genes and overlooking the coordinated interactions that truly drive sensitivity or resistance to treatments.
The scientific community is moving toward more robust and scalable post-hoc frameworks, capable of offering multiple complementary forms of explanation. These systems allow recovering known associations between drugs and genes, validating mechanisms of action, and most interestingly, generating novel hypotheses about molecular signals previously hidden. By integrating these capabilities into a complete analysis pipeline, a more holistic view is achieved: it is no longer about an isolated relevant gene, but about networks of genes that work synergistically.
For these solutions to reach the clinical or pharmaceutical realm, solid technological infrastructure is essential. This is where the value of developing custom applications that implement these artificial intelligence pipelines with guarantees of stability and performance comes in. None of this would be possible without an ecosystem that combines AWS and Azure cloud services to process terabytes of genomic data, nor without cybersecurity to protect sensitive patient and trial information.
From a business perspective, AI for enterprises not only improves diagnostic accuracy but also enables the creation of AI agents capable of suggesting new therapeutic targets. Additionally, business intelligence services based on Power BI visualize response patterns that help R&D teams prioritize experiments. At Q2BSTUDIO, we understand that custom software is the foundation for transforming academic models into operational tools, integrating everything from process automation to advanced analysis.
Building an explanatory framework for oncology drug response therefore requires a multidisciplinary approach where computational biology meets artificial intelligence engineering. Only then can the limitations of traditional methods be overcome, offering researchers not just predictions, but genuine knowledge about the underlying mechanisms of cancer.
